Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease

Annals of Clinical and Translational Neurology

Volumn 3, Issue 1, 2016, Pages 12-20

  Janelidze, Shorena ^a   Hertze, Joakim ^a,b   Zetterberg, Henrik ^c,d   Landqvist Waldö, Maria ^a,b   Santillo, Alexander ^a,b   Blennow, Kaj ^c   Hansson, Oskar ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CHITINASE 3 LIKE PROTEIN 1; GLYCOPROTEIN; NEUROGRANIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MALE; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 84971453132     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.266     Document Type: Article

References (47)

1. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-185.
2. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698-712.
3. Lista S, Zetterberg H, Dubois B, et al. Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. J Neurol 2014;261:1234-1243.
4. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-144.
5. Blennow K, Dubois B, Fagan AM, et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 2015;11:58-69.
6. Pak JH, Huang FL, Li J, et al. Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci USA 2000;97:11232-11237.
7. Zhong L, Brown J, Kramer A, et al. Increased prefrontal cortex neurogranin enhances plasticity and extinction learning. J Neurosci 2015;35:7503-7508.
8. Davidsson P, Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr 1998;10:11-23.
9. Reddy PH, Mani G, Park BS, et al. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis 2005;7:103-117; discussion 73-80.
10. De Vos A, Jacobs D, Struyfs H, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimers Dement 2015; DOI: 10.1016/j.jalz.2015.05.012.
11. Kvartsberg H, Portelius E, Andreasson U, et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimers Res Ther 2015;7:40.
12. Kester MI, Teunissen CE, Crimmins DL, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 2015; DOI: 10.1001/jamaneurol.2015.1867.
13. Portelius E, Zetterberg H, Skillback T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain 2015;138(Pt 11):3373-3385.
14. Bonneh-Barkay D, Bissel SJ, Wang G, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008;173:130-143.
15. Bonneh-Barkay D, Zagadailov P, Zou H, et al. YKL-40 expression in traumatic brain injury: an initial analysis. J Neurotrauma 2010;27:1215-1223.
16. Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010;133(PART 4):1082-1093.
17. Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population. Stroke 2015;46:329-335.
18. Alcolea D, Carmona-Iragui M, Suarez-Calvet M, et al. Relationship between beta-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 2014;42:157-167.
19. Olsson B, Hertze J, Lautner R, et al. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis 2013;33:45-53.
20. Wennstrom M, Surova Y, Hall S, et al. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer's but not Parkinson's disease or dementia with Lewy bodies. PLoS One 2015;10:e0135458.
21. Alcolea D, Martinez-Lage P, Sanchez-Juan P, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology 2015;85:626-633.
22. Sutphen CL, Jasielec MS, Shah AR, et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 2015;72:1029-1042.
23. American Psychiatric Association. Work Group to Revise DSM-III. Diagnostic and statistical manual of mental disorders: DSM-III-R. 3rd ed. Washington, DC: American Psychiatric Association, 1987.
24. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
25. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
26. Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 2005;20(Suppl 12):S11-S20.
27. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
28. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
29. Ewers M, Mattsson N, Minthon L, et al. CSF biomarkers for the differential diagnosis of Alzheimer's disease. A large-scale international multicenter study. Alzheimers Dement 2015; DOI: 10.1016/j.jalz.2014.12.006.
30. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. Available at: http://www.R-project.org/ (accessed October 2014).
31. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
32. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-574.
33. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015;16:358-372.
34. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-791.
35. Perrin RJ, Craig-Schapiro R, Malone JP, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011;6:e16032.
36. Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res 2010;1362:13-22.
37. Kvartsberg H, Duits FH, Ingelsson M, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement 2014;11(10):1180-1190.
38. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-629.
39. Blennow K, Mattsson N, Scholl M, et al. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 2015;36:297-309.
40. van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010;20:881-891.
41. Fagan AM, Shaw LM, Xiong C, et al. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 2011;68:1137-1144.
42. Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010;68:903-912.
43. Antonell A, Mansilla A, Rami L, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J Alzheimers Dis 2014;42:901-908.
44. Blennow K, Wallin A, Agren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-245.
45. Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001;297:187-190.
46. Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 2003;8:343-347.
47. Kakuda N, Shoji M, Arai H, et al. Altered gamma-secretase activity in mild cognitive impairment and Alzheimer's disease. EMBO Mol Med 2012;4:344-352.